|Articles|October 1, 2011
Sponsors Show a Preference for Large CROs
Author(s)Industry Standard Research
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena.
Advertisement
Industry Standard Research has recently published new research titled "Post-marketing Safety Market Dynamics," which deeply dives into the growth and decline of study conduct and outsourcing in the post-marketing safety arena. As with much the company's research, a portion of the work was dedicated to exploring the attitudes and use of service providers in the space. Sponsors identified different types of service providers as "Best Fit," depending on the specific service. And the pattern of winners and losers is variable across all five services tested (Phase IV studies, Signal Management Activities, Risk Management Programs, EU QPPV Service, and Scientific Literature Searches).
However, in spite of their lagging position for signal management activities (and some of the others tested) sponsors continue to express a preference for using large CROs.
Large CROs were voted the best fit for non-interventional Phase IV studies.
What should be made of this dynamic? Why should a buyer prefer to use members of a group they believe are a poor fit for the service, relatively speaking?
Perhaps it is the old adage that "nobody gets fired for hiring IBM." But for our industry it's "nobody gets fired for hiring Quintiles/PPD/PAREXEL/Covance/ICON." Or perhaps in spite of a theoretical good fit, the scope of the work is outgrowing the specialists' capabilities. Your thoughts? Send them to info@ISRreports.com .
—Industry Standard Research,
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
- How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery
September 11th 2025
- How Recent Policy Changes Could Impact Clinical Research
September 10th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Investigational PD-L1 x VEGF-A Bispecific Antibody Demonstrates Strong Overall Response Rate in Phase II Small Cell Lung Cancer Trial
2
Phase III BRUIN CLL-313 Trial Finds Jaypirca Extends Progression-Free Survival in Treatment-Naïve CLL/SLL
3
FDA Fast Tracks Sanofi’s Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration
4
How Recent Policy Changes Could Impact Clinical Research
5